Forbion closes Life Sciences VC Fund at €360m

Forbion IV will primarily focus on investment opportunities in the EU and the UK and only secondarily on US biotechs. As in Forbion III the investment focus will be on biopharma investments. 

Forbion IV will target substantial initial stakes, looking to take lead positions and work alongside entrepreneurial management teams to deliver exceptional financial and societal returns. Forbion has already had considerable success with this strategy via its first three funds, with the €183m Forbion III already delivering four exits including the sale of Rigontec to MSD (Merck & Co.) and the highly successful $100.5m IPO of Replimune on NASDAQ in July 2018.

The fund will build a portfolio of approximately fifteen companies, of which five will be new companies (co)founded by Forbion, so-called “build” opportunities, and ten will be existing, “growth” companies.